Low RCC2 expression was associated with higher cancer stage in all three cohorts (p<0.001, online supplemental tables 4 and 5), but not with any other clinicopathological factors (patient age, sex or tumour location) or molecular markers (KRAS, BRAFV600E, TP53 mutation status or CDX2 expression). This evidence concerns the gene RCC2 and cancer.